Turkova, A., White, E., Mujuru, H. A., Kekitiinwa, A. R., Kityo, C. M., Violari, A., . . . Gibb, D. M. (2021). Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children. The New England journal of medicine, 385(27), 2531-2543. https://doi.org/10.1056/NEJMoa2108793
Citace podle Chicago (17th ed.)Turkova, Anna, et al. "Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children." The New England Journal of Medicine 385, no. 27 (2021): 2531-2543. https://doi.org/10.1056/NEJMoa2108793.
Citace podle MLA (9th ed.)Turkova, Anna, et al. "Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children." The New England Journal of Medicine, vol. 385, no. 27, 2021, pp. 2531-2543, https://doi.org/10.1056/NEJMoa2108793.
Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..